ML385 (Standard)
ML385 (Standard) is the analytical standard of ML385 (HY-100523). This product is intended for research and analytical applications. ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma.
For research use only. We do not sell to patients.
- Purity: 98%
- CAS No.: 846557-71-9
- Formula: C29H25N3O4S
- Molecular Weight:511.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
-
HY-100523
ML385 -
HY-12212
Omaveloxolone -
HY-19543
Brusatol -
HY-13755
Sulforaphane -
HY-112675
4-Octyl itaconate -
HY-N1902
4-Hydroxyphenylacetic acid -
HY-101140
KI696 -
HY-12519
Oltipraz -
HY-Z0548
Methyl 3,4-dihydroxybenzoate -
HY-N1902R
4-Hydroxyphenylacetic acid (Standard) -
HY-14909
Bardoxolone -
HY-N1913
Danshensu
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 846557-71-9
-
Molecular Weight 511.59
-
Formula C29H25N3O4S
-
SMILES
O=C(NC1=NC(C2=CC=C(N(C(C3=C(C)C=CC=C3)=O)CC4)C4=C2)=C(C)S1)CC5=CC(OCO6)=C6C=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Singh A, et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS chemical biology. 2016 Nov 18;11(11):3214-3225. [Content Brief]
[2]. Ji L, et al. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells. Cancer medicine. 2023 Mar;12(5):5688-5702. [Content Brief]
[3]. Yan L, et al. ML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma. Medical oncology (Northwood, London, England). 2024 Nov 07;41(12):309. [Content Brief]
[4]. Ishikawa C, et al. ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia. Leukemia & lymphoma. 2025 Apr;66(4):721-732. [Content Brief]
[5]. Jeong EJ, et al. The Effects of ML385 on Head and Neck Squamous Cell Carcinoma: Implications for NRF2 Inhibition as a Therapeutic Strategy. International journal of molecular sciences. 2024 Jun 27;25(13):7011. [Content Brief]
[6]. Yuan J, et al. ML385 increases ferroptosis via inhibiting Nrf2/HO-1 pathway to enhances the sensitivity of MCF-7 TAMR to tamoxifen. Naunyn-Schmiedeberg's archives of pharmacology. 2025 Nov;398(11):16081-16093. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ML385 (Standard) Related Classifications
HY-100523R Related Classifications
Powered by Bioz
Keywords
- ML385 (Standard)
- 846557-71-9
- Reference Standards
- Keap1-Nrf2
- Ferroptosis
- Apoptosis
- mTOR
- Nrf2
- head and neck squamous cell carcinoma
- PBMCs
- Neh1 domain
- tamoxifen-resistant breast cancer
- lung squamous cell carcinoma
- esophageal squamous cell carcinoma
- Jurkat T cells
- non-small cell lung cancer
- adult T-cell leukemia
- Inhibitor
- inhibitor
- inhibit